Recruiting
Phase 2

Doxil & Hyperthermia

Sponsor:

National Center for Research Resources (NCRR)

Code:

NCT00006433

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Doxil

heat treatment

Study Details

Brief summary:

Purpose: The purpose of this protocol is to evaluate the combination of Doxil chemotherapy and heat treatment for recurrent breast cancer located on the chestwall following mastectomy. This protocol also includes patients with metastatic breast cancer who have not had mastectomy but have advanced tumor remaining within the breast. Doxil is the drug adriamycin (also called doxorubicin) encapsulated in liposomes, which coats the drug with a small amount of lipid (fat). This chemotherapy is in a newer form which can be better delivered to the tumor tissue without causing as much systemic toxicity. We are combining heat treatment with this drug in an effort to further increase the delivery of drug to the tumor, which may give an increased tumor response.

Methods: The patients will be treated with chemotherapy followed by heat treatment. This will be given for 6 cycles approximately every 4 weeks. For the first cycle patients will need to be hospitalized 3 days for measurement of blood levels of drug as well as some additional radiology studies which will help us to determine whether the drug is preferentially distributed within tumor.

Conditions

Breast Cancer

Study ID

NCT00006433

Start date

Jan, 2000

Status verified date

Nov, 2001

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with recurrent or metastatic breast cancer

Study Design

Primary purpose

Treatment

Interventions and Outcome Measures

Interventions

Doxil

heat treatment

Central Contacts and Locations

Central contacts

Janye Blivin, R.N., M.S.N.

1-919-660-2174

Locations

Radiation Oncology, Duke University Medical Center

Recruiting

Durham, North Carolina, United States, 21170

Contacts

Janye Blivin, RN, MSN

919-660-2174

Principal Investigator:

Leonard R. Prosnitz, MD

More Information

Sponsor

National Center for Research Resources (NCRR)

Last update posted

Jun 24, 2005

Last verified

Nov, 2001

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by National Center for Research Resources (NCRR) on 2005-06-24.